Flyer

Acta Rheumatologica

  • Journal h-index: 2
  • Journal CiteScore: 0.29
  • Journal Impact Factor: 0.67
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • OCLC- WorldCat
  • Publons
  • Google Scholar
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Abstract

An Analysis for the Patients who Suffered by Metastatic Bone Disease

Itishree Badatya*

In order to better understand Xgeva-treated treatment-emergent hypocalcemia in patients with bone metastases, this analysis was carried out. Data from three identically designed phase 3 trials of subcutaneous Xgeva 120 mg versus intravenous zoledronic acid 4 mg were used to analyze laboratory abnormalities and hypocalcaemiarelated adverse events in patients with metastatic bone disease. Xgeva was associated with a higher overall rate of laboratory manifestations of hypocalcaemia of grade 2 than zoledronic acid. In most cases, hypocalcaemia events of grade 2 severity occurred within the first six months of treatment. Patients who revealed taking calcium as well as vitamin D enhancements had a lower rate of hypocalcaemia. Significant risk factors for developing hypocalcaemia included prostate cancer or small-cell lung cancer, decreased creatinine clearance, and elevated baseline bone turnover markers of urinary N-telopeptide of type I collagen and bone-specific alkaline phosphatase values. Patients with more than two bone metastases at baseline were more likely to be at risk for elevated BSAP levels than those with fewer than two. Xgeva had a greater antiresorptive effect than zoledronic acid, as evidenced by its higher frequency of hypocalcaemia. Before beginning treatment with a powerful osteoclast inhibitor, low serum calcium levels and potential vitamin D deficiency should be corrected, and corrected serum calcium levels should be monitored throughout treatment. The risk of hypocalcaemia appears to be significantly reduced with adequate calcium and vitamin D intake.

Keywords

Metastatic bone disease; Xgeva; Anti-resorptive effect; Zoledronic acid

Published Date: 2023-04-28; Received Date: 2023-04-01